JACC:高血小板反应性与出血风险关系密切!

2017-08-17 佚名 medicalxpress

根据JACC在线发表的一项研究:药物洗脱支架植入术后,氯吡格雷与高血小板反应性及两年缺血和出血发生率之间存在着密切的关系。

根据JACC在线发表的一项研究:药物洗脱支架植入术后,氯吡格雷与高血小板反应性及两年缺血和出血发生率之间存在着密切的关系。

美国北卡罗来纳州格林斯博罗市Cone Health的Thomas D. Stuckey博士及其同事分析了使用药物洗脱支架研究进行的双重抗心律失常治疗评估的两年期结果,其中8,582例经皮冠状动脉介入治疗后进行常规血小板功能检查药物洗脱支架(2008年至2010年)。


研究人员发现,46.3%的患者在两年内进行再次抗血小板治疗,而不停药。两年来有92例(1.07%)有明确或可能的支架内血栓形成。氯吡格雷的高血小板反应性与连续治疗患者的可能的支架血栓形成具有独立相关性(风险比[HR],2.09; 95%置信区间[CI],1.29?3.82; P = 0.006)。其他关联包括心肌梗塞(HR,1.33; 95%CI,1.04?1.71; P = 0.02),无临床相关性出血(HR,0.78; 95%CI,0.64?0.94; P <0.01),死亡率(调整HR,1.35; 95%CI,1.00?1.84,P = 0.05)。

作者写道:“维持阿司匹林单一疗法超过一年的低风险患者的阿司匹林低反应性并不能预测晚期事件,维持双重抗血小板治疗的高风险患者的高血小板反应性与两年的结果独立相关。评估长期使用二磷酸腺苷抑制作用的未来研究应纳入个体化患者选择,以优化缺血事件,减少与出血之间的关联。
原始出处;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853733, encodeId=662a1853e33a9, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Mar 24 14:04:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028483, encodeId=556d20284830c, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jul 17 16:04:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022791, encodeId=387d2022e9198, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Apr 06 10:04:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325481, encodeId=50ed132548136, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 19 04:04:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234469, encodeId=8af7234469db, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 17 13:52:55 CST 2017, time=2017-08-17, status=1, ipAttribution=)]
    2018-03-24 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853733, encodeId=662a1853e33a9, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Mar 24 14:04:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028483, encodeId=556d20284830c, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jul 17 16:04:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022791, encodeId=387d2022e9198, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Apr 06 10:04:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325481, encodeId=50ed132548136, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 19 04:04:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234469, encodeId=8af7234469db, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 17 13:52:55 CST 2017, time=2017-08-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853733, encodeId=662a1853e33a9, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Mar 24 14:04:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028483, encodeId=556d20284830c, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jul 17 16:04:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022791, encodeId=387d2022e9198, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Apr 06 10:04:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325481, encodeId=50ed132548136, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 19 04:04:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234469, encodeId=8af7234469db, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 17 13:52:55 CST 2017, time=2017-08-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853733, encodeId=662a1853e33a9, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Mar 24 14:04:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028483, encodeId=556d20284830c, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jul 17 16:04:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022791, encodeId=387d2022e9198, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Apr 06 10:04:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325481, encodeId=50ed132548136, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 19 04:04:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234469, encodeId=8af7234469db, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 17 13:52:55 CST 2017, time=2017-08-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853733, encodeId=662a1853e33a9, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Mar 24 14:04:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028483, encodeId=556d20284830c, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jul 17 16:04:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022791, encodeId=387d2022e9198, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Fri Apr 06 10:04:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325481, encodeId=50ed132548136, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 19 04:04:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234469, encodeId=8af7234469db, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 17 13:52:55 CST 2017, time=2017-08-17, status=1, ipAttribution=)]
    2017-08-17 惠映实验室

    学习了,谢谢。

    0

相关资讯

J Periodontal Res:含洗涤或未洗涤血小板释放上清的骨替代材料的释放动力学区别:血小板制备方法的影响

在再生牙科中,应用血小板制剂来刺激骨愈合和牙周再生。我们寻求一种方法用骨替代物作为血小板释放上清液的载体。评估了负荷骨替代物的促有丝分裂能力和释放动力学。

Blood:为何癌症患者容易发生静脉血栓栓塞?

癌症患者发生静脉血栓栓塞(VTE)的风险较高。Yohei Hisada和Nigel Mackman在本文中总结一些癌症患者中常见的以及与癌症类型有特异性的VTE的信号通路。

JAHA:血小板凝聚状态能预测冠心病患者的临床风险?

既往研究表明,在冠心病患者中,在接受抗血小板治疗期间出现不断升高的血小板聚集可能会增加心血管不良事件的发生风险,而大多数冠心病患者接受的是单一的阿司匹林治疗。近日,在国际心血管权威杂志JAHA上发表了一篇旨在评估接受阿司匹林治疗的稳定冠心病患者的高血小板凝聚水平是否会增加心血管不良事件的发生风险的临床研究。本研究纳入了900例有心梗病史或2型糖尿病病史的稳定冠心病患者,所有患者均接受单一的每天75

Nature Biomedical Engineering:国家纳米中心实现肿瘤微环境中肿瘤相关血小板的安全高效清除

中国科学院国家纳米科学中心聂广军课题组长期致力于利用纳米技术靶向和调控肿瘤血管和肿瘤相关血小板的相关研究,近期,在构建环境响应型纳米药物载体,实现安全、高效的肿瘤局部血小板清除,以增强肿瘤血管EPR效应和化疗药物靶向富集方面取得新进展。相关研究成果Nanoparticle-mediated local depletion of tumour-associated platelets disrupt

不依赖献血:日本量产血小板有望获批

据日媒报道,近日,日本国内16家制药和化学相关企业在全球首次确立了利用 “iPS细胞”量产属于血液成分之一的血小板的技术。

Cancer Cell:了解肺癌,这个血液指标很关键!

荷兰的研究人员设计了不同的液体活检方法。通过检测血液循环血小板(也称为血栓细胞)吸收的肿瘤RNA,他们的测试(称为thromboSeq)不是在血液中寻找癌症DNA或其他生物标志物的证据,而是可以以接近90%的准确度诊断非小细胞肺癌。非小细胞肺癌占肺癌的绝大多数。该研究在8月14日刊登在癌症细胞杂志上。